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ABSTRACT 
Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate that 
induces excitotoxic brain cell death. The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) is 
reported to suppress neurotransmitter release through selective activation of presynaptic Group II 
metabotropic glutamate receptors. Therefore, strategies to elevate levels of NAAG following brain injury 
could reduce excessive glutamate release associated with TBI. We hypothesized that the NAAG peptidase 
IIlhih itor. ZJ-43 would elevate extracellul~lr NAAG levels and reduce ext",cellular levels of amino acid 
neurotransmitters following Tl3l by a Group II metabotropic gluta mate receptor (mGluR)-mcdiated 
mechanism. Dialysate levels ofNAAG, glutamate, aspartate and GABA from the dorsal hippocampus 
were elevated after TBI as measured by ill vivo microdialysis. Dialysate levels ofNAAG were higher and 
remained elevated in the ZJ-43 treated group (50 mg/kg, i.p.) compared to control. ZJ-43 treatment also 
reduced the rise of dialysate glutamate, aspartate, and GAB A levels. Co-administration of the Group II 
mGluR antagonist, L Y34 1495 (I mg/kg, i.p.) partially blocked the effects of ZJ-43 on dialysate glutamate 
and GABA suggesting that NAAG effects are mediated through mGluR activation. The results are 
consistent with the hypothesis that inhibition ofNAAG peptidase may reduce excitotoxic events 
associated with TBI. 
Key Words: traumatic brain injury, glutamate, N-acetylaspartylglutamate (NAAG), microdialysis, 
metabotropic glutamate receptor 
Running Title: NAAG PEPTIDASE INHIBITOR REDUCES AMINO ACID NEUROTRANSMITTERS 
AFTER TBI 
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INTRODUCTION 
Traumatic brain injury (TBI) is a serious health problem that results in more than 230,000 
hospitalizations and 50,000 deaths per year in the USA (NIH, (999). However, no truly efficacious and 
approved therapies are currently available for the treatment ofTBI. The search for neurochemical pathways 
of secondary injury after TBI and subsequent development of therapeutic interventions has implicated 
glutamate excitotoxicity as an important mechanism causing neuronal damage through excessive receptor 
activation. For example, extracellular glutamate is elevated immediately after the TBI (Faden et aI., 1989; 
Katayama et aI., 1990; Globus et aI., (995) and significantly contributes to delayed neuronal cell death 
following TBI (Smyth et aI., 2005a, 2005b). Pharmacological blockade of glutamate receptors early after 
TBI improves outcome in laboratory animals (e.g., Hayes et aI., 1988, Faden et aI., 1989; Kawamata et aI., 
1992). Although laboratory results targeting glutamate excitotoxicity have often been impressive, 
translation of this strategy into clinical application, particularly the use of receptor antagonists, remains 
overwhelmingly disappointing (Bullock et aI., 1999; Narayan et aI., 2002). As an alternative strategy, the 
present study examines the possibility of reducing excessive glutamate release following TBI by 
manipulating N-acetylaspartylglutamate (NAAG), an endogenous neuropeptide involved in modulating 
glutamate release. 
NAAG is an abundant peptide neurotransmitter found in millimolar concentrations in the mammalian 
central nervous system (Coyle et aI., 1997; Neale et aI. , 2000). NAAG selectively activates the Group II 
metabotropic glutamate receptor subtype 3 (mGluR3), with about IO-fold less efficacy at mGluR2 
(Wroblewska et aI. , 1993, 1997; 1998; Schweitzer et aI., 2(00). Acting at the presynaptic group II mGluR, 
NAAG has been shown to reduce cAMP levels (Wroblewska et aI., 1993, 1997, (998), decrease voltage-
regulated calcium conductance (Bischofberger and Schild, 1996) and importantly to reduce the synaptic 
release of glutamate and GABA (Zhao et aI., 2001; Xi et aI., 2002; Garrido-Sanabria et al.. 2004). 
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Therefore inhibiting the hydrolysis ofNAAG may be an alternative strate!,,), to attenuate glutamate 
excitotoxicity (reviewed in Neale et aI., 2000; 2005; Zhou et aI., 2005). 
Synaptically released NAAG is rapidly hydrolyzed to form glutamate and N-acetylaspartate (NAA) 
by at least two peptidases, glutamate carboxypeptidase II and III (Luthi-Carter et aI., 1998; Bzdega et aI., 
2004). Potent NAAG peptidase inhibitors have been synthesized by two research !,'!'oups (Jackson et al., 
1996; Jackson & Slusher, 2001; Rong et aI., 2002; Kozikowski et aI., 2001, 2004). These peptidase 
inhibitors were shown to be neuroprotective in a number of glutamate excitotoxicity models (reviewed in 
Neale, et aI., 2005) including ischemic-hypoxic damage (Slusher et al. 1999), inflammatory pain and 
allodynia (Yamamoto et aI., 200la; b; 2004), diabetic neuropathy (Zhang et al. 2002), amyotrophic lateral 
sclerosis (Ghadge et aI., 2003) and phencyclidine induced schizophrenia-like behaviors (Olszewski et aI., 
2004). Excess glutamate release has been implicated in each of these models of human pathological 
conditions. Moreover, recent studies found that systemic administration (immediate post-injury plu, 
repeated dosing at R and Iii hr post-injury) of ZJ-43, a novel NAAG peptidase inhibitor, significantly 
reduced TBI-induced neuron and astrocyte cell death following lateral fluid percussion in rats (Zhong et 
aI., 2005). The selective Group II mGluR antagonist, L Y34 1495, completely abolished the cell death 
attenuation of the NAAG peptidase inhibitor. These data are consistent with the hypothesis that NAAG 
peptidase inhibitors augment an endogenous protective mechanism that reduces e,ciloloxic c\ ents mediated 
by NAAG activation of group II mGluRs. 
In this report, we combined the fluid percussion model and a modified microdialysis technique to lest 
the hypothesis that following TBI, NAAG peptidase inhibition would increase extracellular NAAG levels 
and in tum reduce the release of glutamate and other neurotransmitter such as aspartate and GABA from 
neurons by a Group II mGluR-mediated mechanism. 
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MATERIALS AND METHODS 
Animals: 
Forty-three male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 364 ±23g were used for this 
study. The animals were housed in individual cages in a temperature (22°C) and humidity-controlled (50% 
relative) animal facility with a 12-hr light/dark cycle (light cycle 06:0011 8:00 hr). Water was continually 
available. The Institutional Animal Care and Use Committee at the University of California at Davis 
approved all animal procedures in these experiments. 
ZJ-43 preparation and administration: 
ZJ-43 (C"H2oN20" Mol. WI. 304.2964) was synthesized according to the published methods 
(Kozikowski et aI., 2004). ZJ-43 was dissolved in saline (50 mg/mL). ZJ-43 (50 mglkg) or saline (equal 
volume) were injected i.p. 15 minutes prior to lateral fluid percussion TBI (n=9 per group). This dose was 
chosen based on a previous study in which 50 109/kg of ZJ-43 produced optimal protection in the same TBI 
model (Zhong et aI., 2005). To test the hypothesis that the effect ofZJ-43 may be mediated by augmented 
NAAG activation of Group II mGluR, an additional group was co-administered ZJ-43 (50 mg/kg) and the 
Group II mGluR antagonist, LY341495 (I mg/kg, i.p.), which was predicted to abolish any effects ofZJ-43 
on neurotransmitter levels (Kingston et aI., (998). 
Surgery: 
Rats were anesthetized with 4% isoflurane in a 2: 1 nitrous oxidefoxygen mixture, intubated, and 
mechanically normoventilated with a rodent volume ventilator (Harvard Apparatus model 683, Holliston, 
MA) with isoflurane reduced to 2%. Rats were mounted in a stereotaxic frame, a scalp incision made 
along the midline, and a 4.8mm diameter craniectomy was performed on the left parietal bone (centered at 
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-4.5 mm bregma and lefllateral 3.0 mm). A rigid plastic injury tube (modified Leur-Ioc needle hub, 2.6 
mm inside diameter) was secured over the exposed, intact dura with cyanoacrylate adhesive. Two skull 
screws (2.1 mm diameter, 6.0 mm length) were placed into burr holes, I mm rostral to Breb'l11a and I mm 
caudal to Lambda. A second scalp incision was made from the midline to the left transversely, the soft 
tissues and temporalis muscle divided and reflected, and a small burr hole was made on the left temporal 
bone. A modified guide cannula was angled at45 deb ... ee from vertical and inserted into the burr hole with 
its distal end protruding 1 mm into the brain. The assembly was secured to the skull with cranioplastic 
cement (Plastics One, Roanoke, VA). The depth of the microdialysis probe (2 mm CMNI2, CMA 
Microdialysis, Solna, Sweden) into the brain limited by an 8 mm spacer made from PE 1 00 tubing 
between the microdialysis probe and the guide cannulae. Rats remained ventilated with isoflurane reduced 
to 1 % in a 2: 1 nitrous oxide/oxygen mixture throughout the entire dialysis sampling period. Rectal 
temperature was continuously monitored and maintained within normal ranges during surgical 
preparation by a feedback temperature controller pad (CWE model TC-I 000, Ardmore, PAl. 
Ninety minutes prior to TBI, the microdialysis probe was inserted through the guide cannula for 
optimal placement of the dialyzing membrane within the CA3 region of the left dorsal hippocampus with 
the tip of the dialysis membrane positioned at the following coordinates: AP: -4.5; L: 4.7; V: -4.1 mm 
from bregma according to the rat atlas of Paxinos and Watson (1998). The probe was continuously 
perfused with Ringers solution at a constant flow rate of 2 IlUmin. Microdialysis sample collection was 
adjusted to allow for dead space in the probe and exit tubing (approximately 12 ilL, which cleared in 6 
min). The probe was removed I min prior to TBI and replaced immediately after TBI. An additional 
control group was included to isolate the effects of microdialysis probe removal and reinsertion (probe-
reinsertion control) on amino acid concentrations in uninjured rats (n=6). In this group, animals were treated 
identically to all other groups with the exception that no drug was delivered and TBI was not administered. 
Dialysis sampling aliquots were collected every 15 minutes for 135 min after TBI and immediately 
frozen in powdered dry ice. Frozen microdialysate vials were later analyzed for NAAG, glutamate, 
aspartate, and GABA. The calculated probe efficiency for glutamate recovery was approximately 5-6% 
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when sampling from a 1 mM stock concentration of glutamate. However, dialysate amino acid levels 
reponed in the present study are not corrected for ill vitro rates of recovery because such calibration is not 
directly applicable to in vivo sampling (Hsiao et aI., 1990; Parsons and Justice, 1994). The location of the 
microdialysis probe was verified histologically in each animal at the end of the experiment. 
Induction of TOI: 
Experimental TBI was produced using a fluid percussion device (VCU Biomedical Engineering, 
Richmond, VA) (Dixon et aI., 1987) using the lateral orientation (McIntosh et aI., 1989). The device 
consists of a Plexiglas cylindrical reservoir filled with distilled water. One end of the reservoir has a 
Plexiglas piston mounted on O-rings and the opposite end has a transducer housing with a 2.6 mm inside 
diameter male Leur-loc opening. Injury is induced by the descent of a pendulum striking the piston, which 
injects a small volume of saline epidurally into the closed cranial cavity, producing a brief displacement 
and deformation of neural tissue. The resulting pressure pulse is measured in atmospheres (ATM) by an 
extracranial transducer (Entran Devices, Inc., Fairfield, NJ , model EPN-0300A·-IOOA) and recorded on a 
digital storage oscilloscope (Tektronix Inc. model TDS 1002, Beavenon, OR). 
The rats were disconnected from the ventilator, the injury tube connected to the fluid percussion 
cylinder, and a moderate fluid percussion pulse (range: 2.22 - 2.35 ATM) was delivered within ten 
seconds. Immediately after TBI rats were ventilated with 1% isoflurane in a carrier gas mixture (2: I 
nitrous oxide/oxygen) for the duration of the experiment. 
NAAG assay methods: 
NAAG in dialysate samples was analyzed by radioimmunoassay. This method allows measurement of 
picomole amounts ofNAAG microdialysis samples. A 5-point standard curve was generated using 
["H)NAAG, revealing a linear relationship with high correlation (Fig. I B). Antibody to NAAG was 
produced in rabbits by repeated immunizations with NAAG coupled to thyroglobulin or to colloidal gold. 
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Specificity of serum was detennined by comparing competitive displacement curves for NAAG and 
several related molecules (N-acetylaspartate, aspartyl glutamate, aspartate, and glutamate). 
The radioimmunoassay was perfonned using protein A - agarose (Roche). Ninety microliters of 
protein A - agarose suspensions in microfuge tubes, were washed with 900 ilL PBS, and sedimented at 
2500 x g for 15 seconds. The pellet was resuspended with NAAG antisera, diluted I: 300 with PBS, and 
incubated for 4 hours or overnight on orbital shaker at 4" C. The mixture was sedimented as above, and 
washed with PBS. The pellet was then resuspended in 100 ilL of[lHJ NAAG (25,000 cpm, approximately 
3 pmoles), and 200 ilL of sample or NAAG standard. A standard curve (0.3 to 30 pmoles NAAG) 
including positive and negative controls was perfonned with each assay (Figure I B). The mixture was 
incubated overnight at 4° C, with rotation. The tubes were sedimented as before, and supernatant collected. 
The pellet was washed three times with PBS. Agarose was then transferred to scintillation vials after 
resuspension with 0.2M HCI. The tritium bound to protein A - agarose was counted by liquid scintillation, 
and bound radioactivities of unknown samples were compared to the standard curve. 
Quantification of amino acid concentrations: 
Glutamate and aspartate were detennined by precolumn derivatization of a 10 ilL dialysate 
sample with o-phtaldialdehyde/mercaptoethanol reagent and separation by reversed-phase HPLC on a 
Biophase ODS 5 11M particle column (Knauer, Berlin, Germany). The mobile phase contained 0.1 M 
sodium acetate, 6.25% methanol, 1.5% tetrahydrofurane, pH 6.95 and was perfused at a flow rate of I 
mLlmin. A linear /,'Tadient system was used to clean the column afier elution of glutamate. This involved 
switching to 100% methanol for 2 min before switching back to the original acetate buffer. The excitation 
wavelength in the fluorescence detector (Hitachi FIOOO, Tokyo, Japan) was set at 370 nm and the 
emission cut off filter was set at 450 nm. The limit of detection was 0.5 pmoVsample for glutamate 
(Morari et aI., 1994). 
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The GABA assay was based on precolumn derivatization of a 10 J.lL sample with 0-
phtaldialdehydeft-butylthiol reagent and separation by reversed-phase HPLC on a Nucleosil3 CI8 
column perfused under isocratic conditions at the flow rate of 0.8 mUmin. The mobile phase was 0.15 M 
sodium acetate, I mM EDT A, 50% acetonitrile, pH 5.4. The BAS LC4B electrochemical detector 
(Bioanalytical Systems, West Lafayeue, fN) was set at +0.75 Y. The limit of detection was 50 
fmolfsample (Morari et aI., 1994). 
Statistical Analysis 
All data in the graphs are expressed as mean ± standard error of the mean. Tabular data are expressed as 
mean ± standard deviation. Data analysis for all measurements except NAAG was performed using SPSS 
software (version 11.5). Alpha level for Type I error was set at 0.05 for rejecting null hypotheses. 
Fluid percussion injury magnitudes (in ATM) and temperature measurements were analyzed using 
separate one-way ANOY A between treatment groups. Amino acid concentrations from the four groups at the 
0-15 min post injury dialysate samples were analyzed with one-way ANOY A. Post hoc comparisons were 
made using the Dunnett t (two-sided) test comparing each treatment (vehicle, ZJ-43, ZJ-43+LY341495) with 
the probe-reinsertion control. A similar analysis was also performed on the \5-30 minute post injury dialysate 
samples. 
Data analysis for the NAAG microdialysis was performed using a linear mixed-effects model of drug 
and time (sample) fit by restricted maximum likelihood estimation (REML) using library nlme in R (version 
2.1.\,2005). Five microdialysate samples could not be analyzed due to sample collect problems. Analysis 
oflonb~tudinal data necessarily involves inter-correlated observations within individuals but missing 
observations cause conventional repeated-measures ANOY A to fail or delete entire cases; the mixed-effects 
model enables fiuing of both fixed and random terms despite data loss (Pinheiro & Bates, 2000). This model 
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takes into accountthc loss of degrees of freedom in estimating the mean and produces unbiased estimating 
equations for the variance parameters (Smyth and Yerbyla, 1996). 
RESULTS 
Fluid percussion injury magnitudes between !,'TOUPS ranged from 2.27 to 2.31 ATM. Mean rectal 
temperatures of groups ranged from 36.9 to 37.2"C at the time ofTSI and at the time of the final 
microdialysis sample. There were no significant differences between groups in injury magnitude or rectal 
temperature values (Table I). The modi fied mierodia lysis placement technique achieved accumlc and 
consislcnllargeling (lflh" probe lip inlo the dorsal hippocampus CA3 region in all anllnals. Figure I 
shows Ihe probe lrack in a typical animal post-i njury. 
Dialysate NAAG levels in the dorsal hippocampus: 
Data analysis revealed a significant main effect of drug treatment (p < 0.001). Baseline NAAG levels 
in Ihe vehicl e Irealmenl group (0.144 +1- 0.048 LIM) did nol differ (p '" 0.52) fromlcvds in the ZJ-43 
Irealmenl group (0.(196 +1- 0.035 uM). NAAG levels in the 0-15 min post-injury dialysate samples of the 
vehicle-treated group (2.01~ +1- 0.3')4 uM) and ZJ-43lreatment !,'TOUp (2.892 +1- DAM uM) increased 
- 15-fold and - 25-fold, respeclively, over pre-injury baseline values (Figure IA). Dialysate NAAG levels 
decreased at a slower rale in Ihe ZJ-43 treatment !,'TOUp as indica led by a si!,'Ilificant group by sample time 
interaction (p ~ 0.031). Dialysate NAAG levels in Ihe ZJ-43 treatment group remained elevated (-20-25 
fold) for the duration of the experiment (135 min). In conlrasl, NAAG levels in the vehicle trealment 
group relurned to ncar baseline by the 30-45 min post-injury dialysate sample. 
Dialysate glutamate, aspartate, and GADA levels in the dorsal hippocampus: 
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The time course of changes in dialysate glutamate levels in the different groups is illustrated in Fig. 2. 
In control experiments (n~6) to assess the clTects of probe removal and reinsertion (i.e. the probe-reinscl1ion 
control group) in uninjured rats. dialysate glutamate increased li·om a baseline ofO.RI +,-D.RI uM to 1.52 
T! - 0.42 uM at the 0-15 min post reinsertion sample (p ~ 0.13) and rctumed to near baseline levels at the 15-
30 min sample (0.66 +1- 0.21 uM). Dialysate glutamate levels were significantly different between groups in 
the 0-15 min post-injury dialysate sample [F(3.29)=8.258. p < 0.001]. At this sampling time dialysate 
glutamate levels in the vehicle-treated group were - 20-fold higher than the probe-reinsertion controls (p < 
0.001 Dunnett). Glutamate levels retumed to near baseline by the 15-30 minute post-injury dialysate 
sample [F(3.28)~ 1.224. P = 0.319]. 
Dialysate glutamate levels in the ZJ-43 treatment group, although elevated, were not significantly 
different from probe-reinsertion control (p z 0.176 Dunnett) in the 0-15 min post-injury dialysate sample. 
Thus, at the first sample time point following TBI, ZJ-43 treatment reduced the injury-induced elevation 
in dialysate glutamate levels. Dialysate glutamate levels in the ZJ-43 + LY341495 treatment group were 
significantly higher than probe-reinsertion controls (p = 0.007 Dunnett). Thus, addition of the selective 
Group II mGluR antagonist, L Y341495 reversed the protective effect ofZJ-43 on dialysate glutamate 
levels in the dorsal hippocampus. 
In the probe-reinsertion control group (n~6). dialysme asp<lrtate increased Ii·om a baseline 01"0.12 
+1- 0.0] uM to 0.20 +1- (l.()4 uM at the 0-15 min post reinsertion sample Ip > 0.15) and returned to ncar 
baseline levels at the 15-30 min sample (0.14 +1- 0.07 uM). Dialysate aspartate levels (Fih'llre 3) were 
significantly different between groups in the 0-15 min post-injury dialysate samples [F(3,29)=3.61 0, P = 
0.025]. At this sample time the vehicle-treated group showed a - 5-fold higher dialysate aspartate level 
compared to the probe-reinsertion control (p = 0.0 I Dunnett). Aspartate levels returned to near baseline by 
the 15-30 minute post-injury dialysate sample [F(3,27)=0.933, p = 0041]. 
Dialysate aspartate levels in the ZJ-43 treatment group were not significantly different from the probe-
reinsertion controls (p = 0.56 Dunnett) in the 0-15 min post-injury dialysate sample. Thus, at the first 
sample time point after TBI ZJ-43 treatment reduced the injury-induced elevation in aspartate. In contrast 
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to the dialysis glutamate and GABA levels, dialysate aspartate levels in the ZJ-43 + LY341495 treatment 
group were not significantly higher than probe-reinsertion controls (p = 0.325 Dunnett). 
In the probe-reinsertion control !,'fOUp (n=o). dialysate GABA increaS\!d Irom a p;lseiine of 0.01 I +/. 
O.O()2 uM to (!.O33 +1- 0.013 uM at the 0-15 min post reinsertion sample (1' > 0. 13) and retllrned to near 
baseline levels atlhe 30-45 min sample (0.0 15 +/- (1.005 uM). Dialysate GABA levels (Fib'llre 4) were 
significantly different between groups in the 0-15 min post-injury dialysate samples [F(3,29)=3.862, p = 
0.019]. At this sample time dialysate GABA levels in the vehicle-treated group was -25-fold higher than 
the probe-reinsertion controls (p = 0.0 I Dunnett). GABA concentrations returned to near baseline by the 
15-30 minute post-injury dialysate sample [F(3,27)=1.726, p = 0.185]. Dialysate GABA levels were not 
signitieantly dillerent between treatment groups at subsequent post-injury dia lysate sample times. 
Dialysate GABA levels in the Z1-43 treatment group were not significantly different from control (p '" 
0.32 Dunnett) in the 0-15 min post-injury dialysate sample. Thus, at the first sample time point after TBI, 
ZJ-43 treatment reduced the injury-induced elevation in dialysate GAB A levels. Similar to glutamate, 
dialysate GABA levels in the ZJ-43 + LY341495 treatment group were significantly higher than probe-
reinsertion controls (p '" 0.03 Dunnett). Thus, addition of L Y341495, the Group II mGluR antagonist, 
reversed the protective effect of ZJ-43 on dialysate GABA levels in the dorsal hippocampus. 
DISCUSSION 
We examined four neurotransmitters (NAAG, glutamate, aspartate, and GAB A) in microdialysis 
samples collected from the rat dorsal hippocampus after lateral fluid percussion TBI and found a 
significant increase in the dialysate levels of all four neurotransmitter levels. However, a single 
intraperitoneal injection of the novel NAAG peptidase inhibitor, ZJ-43 (50 mglkg) was associated with a 
robust increase in dialysate NAAG levels and significantly reduced the elevation of glutamate, aspartate 
and GABA levels after TBI. Moreover, the group II mGluR selective antagonist, LY341495, successfully 
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reduced the effects of ZJ-43 on dialysate glutamate and GABA levels. This latter finding indicates that the 
effects of NAAG peptidase inhibition on glutamate and GABA are likely mediated by activation of Group 
II mGluRs. 
Microdialysis studies in TBI: 
Using microdialysis, other investigators have demonstrated changes in extracellular levels of energy-
related metabolites and amino acids in hippocampal and cortical regions following TBI (Faden et aI., 
1989; Katayama et aI., 1990; Globus et aI., 1995). However, the microdialysis techniques used in 
experimental brain injury models varied among studies. In one study, the microdialysis probe was 
inserted into the CAl and dentate areas in the hippocampus through a burr hole separate from a near 
midline craniotomy used for administration of a fluid percussion injury (Katayama et aI., 1990). In 
another study, the dialysis probe was placed into the parietal cortex posterior and ipsilateral to the fluid 
percussion craniotomy (Globus et aI., 1995). Other studies inserted the dialysis probe directly through the 
fluid percussion craniotomy afier administration of the lateral fluid percussion TBI (Dixon et aI., 1996; 
Bentzer et aI., 2000; Alves et aI., 2005). Herein, we modified the microdialysis technique in combination 
for use with the fluid percussion rat trauma model by making a small burr hole in the temporal bone and 
then inserting the modified guide cannula and dialysis probe at a 45 degree angle from vertical with the 
probe's tip protruding directly in the CA3 region of the dorsal hippocampus ipsilateral to TBI. There may 
be at least two advantages with this modification. First, the probe's dialysis membrane was directly 
positioned just under the brain impact site. This approach should provide sensitive detection of alterations 
in the traumatized hippocampus. Moreover, inserting the probe through a separate burr hole in the 
temporal bone leaves the dura intact at the site of fluid percussion impact and thus minimizes any probe 
interference with the site of fluid percussion impact. Histological examination or brains Ii'om the present 
study indicated that the microdialysis probe rel iably reached the targeted C A3 region of the dorsal 
hippocampus. 
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Factors influencing dialysate amino acid neurotransmitter levels: 
In the anesthetized preparation used in the present study, microdialysis probes typically require a I hour 
stabilization period before analyte concentration in the fluid returns to levels thought to represent nonnal 
physiological levels in the extracellular space. As such there is a potential problem with withdrawing the 
probe from the brain just prior to TBI and reinserting it immediately after the fluid percussion impact down 
the same track. An alternative is to leave the probe in the brain, but this is likely to cause local tissue 
shearing against the dialysis probe during brain movement at the time of fluid percussion impact (Globus et 
aI., 1995). Moreover, measurement of neurotransmitters by microdialysis has many potential artifacts, not the 
least of which is the trauma induced by the probe implantation itself. The initial probe insertion was 
associated with a large but transient increase in dialysate amino acid neurotransmitter levels (data not shown). 
However, our control experiments to assess the effects of probe removal and reinsertion (i.e. probe-
reinsertion control) in uninjured rats found only a small increase in dialysate glutamate levels following 
probe reinsertion that rapidly returned to baseline within 15 minutes. This reinsertion method has been 
successfully perfonned by a number of investigators (Katayama et aI., 1990; Globus et aI., 1995; Kawamata 
et aI., 1995) as well as in our own laboratory. 
Glutamate excitotoxicity is a significant detenninant ofTBI pathophysiology. Numerous laboratory 
studies (Faden et aI., 1989; Katayama et aI., 1990; Nilsson et aI., 1990) and several clinical studies 
(Zauner et aI., 1996; Bullock et aI., 1998; Koura et aI., 1998) have documented an excessive glutamate 
release following TBI. Experimental cerebral ischemia is also associated with a large, rapid increase in 
extracellular glutamate (Choi and Rothman, 1990; Benveniste et aI., 1984; Globus et aI., 1988, 1991). The 
mab'11itude and the temporal profile of these increases varied among studies, which may be due 
differences in microdialysis methods and the fact that the microdialysis sampling was perfonned in 
different brain regions (i.e., hippocampus, cortex, etc. and probe implantation adjacent to or directly 
within the injury site). In the present study, -20-fold increases in dialysate glutamate levels were 
observed in the first sample collected after impact (0-15 min sample) and returned to near baseline 15-30 
min post-injury. It is importanllo consIder Ihali()lIowing TBllhere arc pCllential "secondary"' sources of 
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glutamate including blood (via BBB leakage), inhibition or reversal of glutamate transporters 
(predominantly on astrocyles) , and hydrolysis ofNAAG (Hillered et al.. 2005: Zhou et aI., 2005). NAAG 
peptidase inhibition would li kely reduce both syoaptic vesicular release and glutamate from NAAG 
hydrolysis . Since ZJ-43 did not completely eliminate the elevation in extracellular glutamate. the data 
suggest other secondary sources may have contributed to the elevated glutamate measured post TBI. 
Our data also documented a smaller magnitude, transient elevation in the dialysate levels of aspartate 
after TBI. This is similar to the previous descriptions of injury-related alterations in extracellular levels of 
neurotransmitter amino acids (Faden et aI., 1989; Nilsson et aI., 1990; Palmer et aI., 1994). The present 
results support the potential role of glutamate and aspartate as mediators of excitotoxic cell injury 
following TB I. An elevation in dialysate GABA levels (-25-fold) similar to that of dialysis glutamate 
levels was observed immediately after injury. Microdialysis sampling of GAB A after TBI or ischemia has 
not been previously reported. The exact mechanism by which both the potentially cylotoxic (i.e., 
glutamate and aspartate) and protective (i.e., GABA) amino acid neurotransmitters increase in the 
extracellular space at the same time after trauma will require further studies although speculation that 
such elevations may be reflect changes in cellular flux or breakdown of the blood brain barrier or both 
(Palmer et aI., 1994). Another possible explanation is that dialysate GABA levels may also be a sensitive 
index of acute excitoxicity and the pronounced elevation in GABA in the dorsal hippocampus may be 
mediated by excessive local NMDA receptor activation (Zeevalk and Nicklas, 1993; Palmer et aI., 1994). 
Moreover, the elevation in GABA could possibly blunt the excitatory actions associated with increased 
levels of glutamate and aspartate (Palmer et aI., 1994). 
Potentiating the effect ofNAAG by peptidase inhibition: 
NAAG serves as a co-transmitter with several small amino acid transmitters, including glutamate and 
GABA (Coyle et aI., 1997; Neale et aI., 2000). serves as a modulator of neurotransmitter release 
(Bischofberger and Schild, 1996; Zhao et aI., 2001; Xi et aI., 2002; Garrido-Sanabria et aI., 2004). Little 
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is known about the alteration ofNAAG level following TBl. Our data indicate a large increase (- 25-fold) 
in dialysate NAAG levels 15 minute after TBI, which returned to near baseline 45-60 minute post-injury. 
A series of novel NAAG peptidase inhibitors have been shown to act as potent neuroprotective or 
neuroactive agents through attenuating the influence of glutamatergic transmission under pathological 
conditions (reviewed in Neale et aI., 2005; Zhou et aI., 2005). Among them, the urea-based NAAG 
analogue, ZJ-43, was shown to act as a potent inhibitor ofNAAG peptidases, GCP 11 (K, ~0.8 nm) and 
GCP 111 (Ki =23 nm) that breakdown NAAG following synaptic release (Bzdega et al. 2004; Olszewski et 
al. 2004). A previous study performed by this group showed that intraperitoneal administration ofZJ-43 
at the 50 mg/kg dose significantly reduced both neuronal and astrocyte damage in the dorsal hippocampus 
following TBI (Zhong et aI., 2005). In the present study, a single intraperitoneal injection of ZJ-43 at the 
50 mglkg dose was associated with a robust and prolonged increase in dialysate NAAG levels for over 2 
hours and this paralleled a significant reduction in the TBI-induced release of glutamate, aspartate and 
GABA. 
Reversal of the effects of ZJ-43 by L Y341495: Possible mechanisms and implications: 
The selective Group 11 mGluR antagonist, L Y341495, blocked the effects of ZJ-43 on dialysate 
glutamate and GABA levels in the dorsal hippocampus. However, the inability of L Y341495 to reverse 
the ZJ-43-induced reduction in dialysate aspartate levels suggests a smaller neuronal pool for this amino 
acid and/or a lack of Group 11 mGluRs located on aspartate containing elements in the dorsal 
hippocampus. Another possibility is that bre"kdown ofNAA by aspa11oacyc1ase Illay contribute to the 
SI'urce of excessive aspartate. If so. inhibition of NAAG peptidase by Z.I-43 would reduce aspartate levcls 
by reducing available NAA and the addition of LY341495 would not block the e tlc ct, Z.I-43. These data 
are consistent with previous findings showing that the protective effects on neurons and astrocytes were 
completely lost when LY341495 was co-administered with ZJ-43 (Zhong et aI., 2005). LY341495 was 
similarly effective in blocking the therapeutic effects ofZJ-43 in animal models of pain and schizophrenia 
(Yamamoto et aI., 2004; Olszewski et aI., 2004). Since ZJ-43 was associated with a significant rise in 
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dialysate NAAG levels and NAAG is selective for mGluR3, the protection is likely due to the enhanced 
activation of this group II subtype. Thus, the present findings strongly suggest that the protection afforded 
by ZJ-43 is mediated by the activation of group II mGluRs in the dorsal hippocampus. 
Pharmacological activation of Group II mGluRs provides neuronal protection in il1l'ill"o injury cell 
injury models (Allen et aI., 1999) and ill I'il'o TBI models (Allen et aI., 1999; Zwienenberg et aI., 2001). 
Furthermore, direct application ofNAAG, which activates Group II mGluRs, reduces NMDA-induced 
toxicity in cultured mouse cortical cells (Bruno et aI., 1998). Pre-stroke administration of the NAAG 
peptidase inhibitor (2-PMPA) in rats decreases dialysate glutamate and lesion volume and improves 
behavioral performance following transient middle cerebral artery occlusion in rats (Slusher et aI., 1999). 
The ability ofNAAG to activate presynaptic mGluRs and inhibit glutamate release (Xi et aI., 2002; 
Garrido-Sanabria et aI., 2004) further supports the conclusion that NAAG peptidase inhibitors such as ZJ-
43 exert their therapeutic effects by elevating extracellular NAAG levels in the dorsal hippocampus which 
then activate local mGluR3. 
Other studies have shown that NAAG peptidase inhibitors provide benefit in a number of models 
including amyotrophic lateral sclerosis (Ghadge et aI., 2003), diabetic neuropathy (Zhang et aI. , 2002), 
allodynia (Yamamoto et aI., 2001), neuropathic and inflammatory pain (Yamamoto et aI., 2004), and 
phencyclidine induced schizophrenia-like behaviors (Olszewski et aI., 2004). Excess glutamate release 
has been implicated in each of these models of human pathological conditions. These applications have 
supported the contention that NAAG peptidase is a significant therapeutic target. 
The strategy of inhibiting NAAG peptidase and subsequent NAAG hydrolysis may afford brain 
protection from TBI in several ways. First, inhibition ofNAAG peptidase activity, resulting in an increase 
of endogenous NAAG, could provide neuroprotection through activation of group II metabotropic 
receptors and subsequent reduction in the release of glutamate (Neale et aI., 2005). Second, blockade of 
NAAG peptidases could have neuroprotectivc effects by reducing a secondary source of glutamate as a 
byproduct ofNAAG hydrolysis (Slusher et al. 1999). The data presented here and elsewhere argue 
against this interpretation inasmuch as the NAAG levels are up to \0 fold lower than the glutamate levels 
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and thus not possibly responsible for the changes in the glutamate levels. Third, astrocytes also express 
group II mGluRs (Wroblewska et aI., 1998; Ferraguti et aI., 2001; Aronica et aI., 2003). Selective 
activation of Group II mGluRs on astrocytes stimulates the release ofneuroprotective factors (Bruno et aI., 
1998). Activation of Group II mGluRs on astrocytes also positively modulate the expression of glutamate 
transporters, increasing the ability of astrocytes to remove glutamate from the synapse (Aronica et aI., 
2003). Finally, inhibition ofNAAG peptidase would also decrease a synaptic source ofNAA which is 
transported into astrocytes along with sodium. Thus, reduced transport ofNAA would likely reduce the 
sodium load on astrocytes and limit potential mechanisms of astrocyte edema. Thus, blockade ofNAAG 
peptidases offers a multi-fold potential for neuroprotection against glutamate excitotoxicity and 
subsequently reduces both astrocyte and neuronal damage under pathological conditions. This strategy 
represents a novel method of reducing the damaging glutamate release associated with TBI by 
augmenting the brain's natural endogenous system of controlling glutamate release via presynaptic 
feedback on mGluR3 by the NAAG peptide. 
In summary, treatment with the NAAG peptidase inhibitor ZJ-43 produced significant protection that 
increased dialysate NAAG levels and decreased excessive dialysis levels of glutamate and other 
neurotransmitters such as aspartate and GABA associated with TBI. The data presented herein support the 
hypothesis that inhibition ofNAAG peptidase may decrease the magnitude and duration of excitotoxic 
events associated with TBI and represent a new potential therapeutic approach to TBI treatment. 
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FIGURE LEGENDS 
Fib""C I . Microdialysis probe track. 
A typical example of the track orthe microdialysis probe showing the location of the 
probe tip into the dorsal hippocampus CA3 sector. Brains were removed unperfused from the 
skull at the end of the microdialysis sampling. A single coronal razor cut was made to identify 
and conlinn correct placement into the target region. 
Figure 2. Time course of dialysate NAAG levels and NAAG radioimmunoassay standard curve. 
A) TBI was induced 15 min after administration of either saline vehicle or ZJ-43. Dialysate NAAG 
levels in the first post-TBI sample increased approximately 15-fold in the vehicle-treated b'TOUP compared 
to pre-injury baseline values. In contrast, dialysate NAAG levels increased approximately 25-fold in the 
ZJ-43 group compared to baseline and remained elevated for over two hours after TBI. Differences 
between groups were signilicant over l)(Isl-injury sample periods stm1ing al the 15-30 min sample (p " 
0.05). Thus, a single i.p. injection ofZJ-43 was associated with a robust increase in dialysate NAAG levels. 
B) A typical NAAG radioimmunoassay standard curve shows linear detection of dialysate NAAG over a 
range of 0.3 to 30 pmoles. • signilics p " 0.05 (Bonfcrroni) compared to vchicle treatment group. 
Fib'llre 3. Time course of dialysate glutamate levels. 
TBI was induced 15 min after administration of either saline vehicle, ZJ-43, or ZJ-43 + L Y342495. A 
control group assessed the effects of probe removal and reinsertion without drug treatment or TBI. Dialysate 
glutamate levels in the vehicle-treatment group were significantly elevated compared to probe-reinsertion 
controls in the first post-injury dialysate sample. Dialysate glutamate levels in the ZJ-43 treatment group 
were not significantly different from probe-reinsertion control in the first post-injury dialysate. Thus, ZJ-43 
administration was associated with a significant reduction in the elevation of glutamate levels after TBI. 
Dialysate glutamate levels in the ZJ-43 + L Y341495 group were significantly elevated compared to control 
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indicating that L Y342495 reversed the protective effect of ZJ-43 on dialysate glutamate levels in the dorsal 
hippocampus. • signifies p < 0.05 compared to probe-reinsertion control. 
Fib'lJre 4. Time course of dialysate aspartate levels. 
Either vehicle, ZJ-43, or ZJ-43 + LY342495 was administered 15 min prior to TBI. Dialysate aspartate 
levels in the vehicle-treatment group were significantly elevated compared to probe-reinsertion controls in 
the first post-injury dialysate sample. Dialysate aspartate levels in the ZJ-43 treatment group and the ZJ-43 + 
L Y341495 group were not significantly different from probe-reinsertion control in the first post-injury 
dialysate sample. Thus, ZJ-43 administration was associated a significant reduction in the elevation of 
aspartate levels after TBI. • signifies p < 0.05 compared to probe-reinsertion control. 
Figure 5. Time course of dialysate GABA levels. 
Vehicle, ZJ-43, or ZJ-43 + LY342495 was administered 15 min prior to TBI. Dialysate GABA levels in 
the vehicle-treatment group treatment group were significantly elevated compared to probe-reinsertion 
controls in the first post-injury dialysate sample. Dialysate GABA levels in the ZJ-43 treatment group were 
not significantly different from probe-reinsertion control in the first post-injury dialysate sample. Thus, ZJ-
43 administration was associated a significant reduction in the elevation of GABA levels after TBI. 
Dialysate GABA levels in the ZJ-43 + L Y341495 group were significantly elevated compared to control 
indicating that L Y342495 reversed the protective effect of ZJ-43 on dialysate GABA levels in the dorsal 
hippocampus. • signifies p < 0.05 compared to probe-reinsertion control. 
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Table I. Injury magnitude and body temperature (values are mean ± S.D.) 
Treatment Group 
NAAG Experiment 
Vehicle (saline) 
ZJ-43 50 mglkg 
ATM 
2.27±O.04 
2.29±O.04 
GlulamatclAspartatclGABA Exocriment 
Vehicle (saline) 
ZJ-43 50 mglkg 
ZJ-43 + LY341495 
2.30±O.015 
2.29±O.02 
2.29±O.02 
Figure I MicrOllialysis probe location 
Temperature (0C) 
Rectal Rectal 
AtTBI 
36.9±O.37 
37.2±O.21 
37.0±O.21 
37.I±O.11 
36.9±O.32 
TBI + 120 min 
37.1±0.13 
37.2±0.29 
37.0±O.22 
36.9±O.26 
37.2±O.21 
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Figure 2 NAAG microdialysis and RIA standard curve 
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Figure 3 Glutamate microdialysis 
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Figure 5 GABA microdialysis 
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